Literature DB >> 27308543

A butterfly effect in cancer.

Peter K Vogt1, Jonathan R Hart1, John R Yates2.   

Abstract

A point mutation in PIK3CA, the gene encoding the α isoform of class I phosphatidylinositol 3-kinase, induces extensive remodeling of the transcriptome and proteome, resulting in a gene signature that specifically resembles that of the basal subtype, but not other types, of breast cancer.

Entities:  

Keywords:  breast cancer; gene signature; phosphatidylinositol 3-kinase; proteome; transcriptome

Year:  2015        PMID： 27308543      PMCID： PMC4845179          DOI： 10.1080/23723556.2015.1029063

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

Review 2.  Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs.

Authors:  Thomas C Roberts; Kevin V Morris; Marc S Weinberg
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

3.  The butterfly effect in cancer: a single base mutation can remodel the cell.

Authors:  Jonathan R Hart; Yaoyang Zhang; Lujian Liao; Lynn Ueno; Lisa Du; Marloes Jonkers; John R Yates; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-12       Impact factor: 11.205

4.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Authors:  Yardena Samuels; Luis A Diaz; Oleg Schmidt-Kittler; Jordan M Cummins; Laura Delong; Ian Cheong; Carlo Rago; David L Huso; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

Review 5.  Phosphatidylinositol 3-kinase: the oncoprotein.

Authors:  Peter K Vogt; Jonathan R Hart; Marco Gymnopoulos; Hao Jiang; Sohye Kang; Andreas G Bader; Li Zhao; Adam Denley
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

6.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

Authors:  Sohye Kang; Andreas G Bader; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-12       Impact factor: 11.205

Review 7.  PI3K pathway alterations in cancer: variations on a theme.

Authors:  T L Yuan; L C Cantley
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

8.  Knockin of mutant PIK3CA activates multiple oncogenic pathways.

Authors:  John P Gustin; Bedri Karakas; Michele B Weiss; Abde M Abukhdeir; Josh Lauring; Joseph P Garay; David Cosgrove; Akina Tamaki; Hiroyuki Konishi; Yuko Konishi; Morassa Mohseni; Grace Wang; D Marc Rosen; Samuel R Denmeade; Michaela J Higgins; Michele I Vitolo; Kurtis E Bachman; Ben Ho Park
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

9.  Activation of diverse signalling pathways by oncogenic PIK3CA mutations.

Authors:  Xinyan Wu; Santosh Renuse; Nandini A Sahasrabuddhe; Muhammad Saddiq Zahari; Raghothama Chaerkady; Min-Sik Kim; Raja S Nirujogi; Morassa Mohseni; Praveen Kumar; Rajesh Raju; Jun Zhong; Jian Yang; Johnathan Neiswinger; Jun-Seop Jeong; Robert Newman; Maureen A Powers; Babu Lal Somani; Edward Gabrielson; Saraswati Sukumar; Vered Stearns; Jiang Qian; Heng Zhu; Bert Vogelstein; Ben Ho Park; Akhilesh Pandey
Journal:  Nat Commun       Date:  2014-09-23       Impact factor: 14.919
  9 in total
  1 in total

1.  Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate.

Authors:  Larissa S Moniz; Silvia Surinova; Essam Ghazaly; Lorena Gonzalez Velasco; Syed Haider; Juan Carlos Rodríguez-Prados; Inma M Berenjeno; Claude Chelala; Bart Vanhaesebroeck
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.